Acetyl-RELA (K221) Antibody

What is Acetyl-RELA (K221) Antibody and what does it specifically detect?

Acetyl-RELA (K221) Antibody is a polyclonal antibody typically produced in rabbits that specifically recognizes RELA (p65) protein only when acetylated at lysine 221. RELA is a critical component of the NF-κB complex, which regulates the expression of genes involved in immune and inflammatory pathways. This antibody serves as a valuable research tool for studying post-translational modifications of NF-κB signaling .

The antibody is designed to detect endogenous levels of NF-κB p65 protein exclusively when acetylated at the K221 residue, making it useful for investigating specific acetylation-dependent regulatory mechanisms. Structurally, this antibody is generated using synthesized acetyl-peptides derived from the internal region of human NFκB-p65 surrounding the K221 acetylation site .

How does acetylation at K221 affect RELA function compared to unmodified RELA?

Acetylation of RELA at lysine 221 significantly impacts its functional properties in several ways:

• Enhanced DNA binding: K221 acetylation increases the DNA binding capacity of NF-κB

• Reduced IκB association: Together with acetylation at K218, K221 acetylation impairs RELA's association with inhibitory IκB proteins, promoting nuclear retention

• Transcriptional activity: This modification is necessary for the full transcriptional potential of NF-κB and affects the expression of specific target genes involved in immune response and inflammation

This site-specific acetylation represents a key post-translational regulatory mechanism that fine-tunes NF-κB activity in response to various cellular stimuli such as inflammatory cytokines, providing an additional layer of control beyond the classical IκB-regulated pathway .

What is the relationship between K221 acetylation and other post-translational modifications of RELA?

RELA undergoes multiple post-translational modifications that create a complex regulatory network. The relationship between K221 acetylation and other modifications includes:

These site-specific modifications create a "modification code" that allows for precise regulation of different aspects of NF-κB function. The interplay between these modifications is critical for determining the duration, strength, and specificity of NF-κB-mediated transcriptional responses .

What are the optimal protocols for detecting acetylated RELA (K221) in cell culture models?

For optimal detection of acetylated RELA (K221) in cell culture models, researchers should follow these methodological approaches:

Direct Western Blotting Protocol:

• Stimulate cells with appropriate activators (e.g., 10 ng/ml TNFα for 30-40 minutes)

• Include deacetylase inhibitors (e.g., 1 μM TSA, 5 mM Nicotinamide) during treatment

• Prepare whole cell extracts using buffers containing deacetylase inhibitors

• Load 30-40 μg protein for SDS-PAGE analysis

• Use Acetyl-RELA (K221) antibody at dilutions of 1:500-1:2000

• Include proper controls (stimulated vs. unstimulated, acetylation-deficient mutants)

Immunoprecipitation-Enhanced Detection:

• Prepare cell lysates (750 μg protein recommended) in Co-IP buffer containing deacetylase inhibitors

• Immunoprecipitate with general anti-RELA antibody (1.5 μg antibody per IP)

• Perform Western blot using Acetyl-RELA (K221) specific antibody

• This approach concentrates the target protein for enhanced sensitivity

Overexpression System for Validation:

• Transfect cells with expression vectors for RELA and p300 acetyltransferase (4:1 ratio)

• Stimulate cells as above

• Detect acetylated RELA by Western blot

• This system provides a positive control with higher acetylation levels

These protocols should be optimized for specific cell types and experimental questions, with special attention to preserving acetylation status throughout sample processing .

What controls are essential when using Acetyl-RELA (K221) Antibody in research applications?

Rigorous experimental design for Acetyl-RELA (K221) Antibody applications requires the following essential controls:

Positive Controls:

• Cells overexpressing both RELA and p300 acetyltransferase

• Samples treated with deacetylase inhibitors (TSA, Nicotinamide)

• Cells stimulated with TNFα or other NF-κB activators

• In vitro acetylated recombinant RELA using p300 and acetyl-CoA

Negative Controls:

• Acetylation-deficient K221R mutant (lysine to arginine mutation)

• Unstimulated cells (basal acetylation levels are typically low)

• p300 knockout/knockdown cells

• Samples without primary antibody to assess secondary antibody specificity

Validation Controls:

• Peptide competition assays using acetylated and non-acetylated peptides

• Parallel detection with antibodies against total RELA to normalize signals

• Comparison with other acetylation site-specific antibodies (K310, K314/315)

• Treatment with site-specific deacetylases when known

When interpreting results, researchers should consider the relative abundance of acetylated versus total RELA protein, as even under stimulated conditions, only a fraction of the total RELA pool may be acetylated at K221 .

How can Acetyl-RELA (K221) Antibody be used in chromatin immunoprecipitation (ChIP) studies?

While the search results don't specifically mention ChIP applications for the Acetyl-RELA (K221) antibody, the following methodological approach can be developed based on principles of acetylation-specific ChIP studies:

ChIP Protocol Development:

• Crosslinking: Fix cells with 1% formaldehyde (10 minutes at room temperature)

• Chromatin preparation: Sonicate to generate 200-500bp fragments

• Pre-clearing: Use protein A/G beads to reduce background

• Immunoprecipitation:

  • Use 2-5 μg of Acetyl-RELA (K221) antibody per ChIP reaction

  • Include parallel IPs with total RELA antibody and IgG control

  • Consider sequential ChIP (Re-ChIP) with other modification-specific antibodies

• Washing and elution: Use stringent washing to ensure specificity

• Analysis: Perform qPCR for known NF-κB target genes or ChIP-seq for genome-wide profiling

Critical Considerations:

• Pre-treat cells with deacetylase inhibitors to preserve K221 acetylation

• Include acetylation-deficient RELA mutant (K221R) controls when possible

• Compare binding profiles of K221-acetylated RELA with total RELA occupancy

• Validate key findings with multiple primers targeting the same promoter regions

This approach allows researchers to determine the specific genomic targets of K221-acetylated RELA and how this modification affects DNA binding selectivity compared to total RELA binding patterns .

How can Acetyl-RELA (K221) Antibody be used to study the dynamics of NF-κB activation in inflammatory diseases?

Acetyl-RELA (K221) Antibody offers powerful approaches for investigating NF-κB activation dynamics in inflammatory disease models:

Temporal Profiling Methodology:

• Establish time-course experiments in cellular or animal models of inflammation

• Collect samples at defined intervals following inflammatory stimuli

• Perform Western blotting with Acetyl-RELA (K221) antibody alongside total RELA detection

• Correlate acetylation patterns with inflammatory gene expression profiles

• Compare acetylation kinetics between acute vs. chronic inflammation models

Cell-Type Specific Analysis:

• Isolate different immune cell populations from inflammatory tissues

• Compare K221 acetylation patterns across cell types

• Correlate with cell-specific inflammatory responses

• Use flow cytometry with permeabilization for intracellular Acetyl-RELA (K221) detection

Pharmacological Intervention Studies:

• Treat inflammatory models with therapeutic compounds

• Assess impact on K221 acetylation status

• Correlate changes in acetylation with therapeutic efficacy

• Target upstream regulators of K221 acetylation to develop novel anti-inflammatory approaches

Clinical Translation:

• Compare K221 acetylation in patient samples vs. healthy controls

• Correlate acetylation levels with disease severity markers

• Assess acetylation patterns before and after therapeutic intervention

• Identify patient subsets with distinct acetylation profiles that may predict treatment response

These approaches provide mechanistic insights into how K221 acetylation contributes to inflammatory pathology and may reveal new therapeutic targets for modulating NF-κB activity in inflammatory diseases .

What techniques can determine if K221 acetylation affects interactions between RELA and other proteins?

To investigate how K221 acetylation influences RELA's protein interaction network, researchers can employ the following methodological approaches:

Affinity Purification-Mass Spectrometry (AP-MS):

• Immunoprecipitate acetylated RELA using Acetyl-RELA (K221) antibody

• Analyze co-precipitating proteins by mass spectrometry

• Compare interaction profiles with non-acetylated RELA

• Validate key interactions through reciprocal co-immunoprecipitation

Proximity-Dependent Labeling:

• Fuse RELA to BioID or APEX2 proximity labeling enzymes

• Compare protein labeling patterns between wild-type and K221R/Q mutants

• Identify proteins that differentially associate based on K221 acetylation status

Co-immunoprecipitation with Acetylation Manipulation:

• Treat cells with acetyltransferase activators/inhibitors or deacetylase inhibitors

• Immunoprecipitate with Acetyl-RELA (K221) antibody

• Blot for specific interaction partners of interest

• Compare with immunoprecipitation using total RELA antibody

Structural Biology Approaches:

• Generate recombinant RELA with acetyl-lysine at position 221 using genetic code expansion

• Perform binding assays with potential interaction partners

• Determine binding kinetics and affinity changes due to acetylation

• Consider X-ray crystallography or cryo-EM to visualize structural changes

Based on search results, K221 acetylation (along with K218) impairs RELA's association with IκB proteins, which represents a critical regulatory interaction in the NF-κB pathway . This suggests K221 acetylation may influence multiple protein-protein interactions that control NF-κB activity and nuclear retention.

How can researchers distinguish between the effects of K221 acetylation versus other RELA acetylation sites?

Distinguishing the specific contribution of K221 acetylation from other RELA acetylation sites requires strategic experimental approaches:

Site-Specific Mutational Analysis:

• Generate single and combined lysine-to-arginine (K→R) mutants:

  • K221R (prevents K221 acetylation)

  • K310R, K314/315R (prevents acetylation at other sites)

  • Combinatorial mutants (K221R+K310R, etc.)

• Compare functional outcomes (DNA binding, transcriptional activity, protein interactions)

• Assess site interdependence through epistasis analysis

Domain-Specific Effects Analysis:

• Map the impact of each acetylation site on specific RELA domains:

  • K221 acetylation may primarily affect DNA binding and IκB association

  • K310 acetylation impacts transcriptional activation

  • K314/315 affects specific target gene subsets

• Use domain-specific functional assays to isolate effects

Temporal Dynamics Comparison:

• Perform precise time-course experiments following NF-κB activation

• Use site-specific acetylation antibodies in parallel

• Determine if different sites follow distinct kinetic patterns

• Correlate with functional outcomes at each time point

Site-Specific Enzymatic Regulation:

• Identify acetyltransferases and deacetylases that specifically target K221

• Compare with enzymes regulating other sites (e.g., SIRT1 deacetylates K310)

• Use enzyme inhibitors/activators to selectively modulate specific sites

Acetylation-Mimetic Approach:

• Generate lysine-to-glutamine (K→Q) mutants to mimic constitutive acetylation

• Compare phenotypes of different acetylation-mimetic mutants

• Assess functional redundancy or antagonism between sites

These approaches help delineate the specific contribution of K221 acetylation to NF-κB regulation and distinguish it from the effects of other acetylation sites .

What are common problems encountered when using Acetyl-RELA (K221) Antibody and how can they be resolved?

When working with Acetyl-RELA (K221) Antibody, researchers may encounter several technical challenges that can be addressed through systematic troubleshooting:

Problem 1: Weak or Absent Signal
Potential Solutions:

• Enhance acetylation levels by treating cells with deacetylase inhibitors (TSA, Nicotinamide)

• Optimize antibody concentration (try 1:500 dilution instead of 1:2000)

• Increase protein loading (50-75 μg instead of standard 30-40 μg)

• Consider immunoprecipitation to concentrate target protein before Western blotting

• Extend primary antibody incubation time (overnight at 4°C)

• Use more sensitive detection systems (enhanced chemiluminescence substrates)

Problem 2: High Background or Non-specific Bands
Potential Solutions:

• Optimize blocking conditions (5% BSA may be preferable to milk for acetyl-lysine detection)

• Increase washing stringency and duration

• Pre-absorb antibody with non-acetylated peptide

• Titrate antibody to lower concentration (1:2000-1:5000) if concentration is too high

• Use freshly prepared buffers and reagents

Problem 3: Inconsistent Results Across Experiments
Potential Solutions:

• Standardize cell stimulation protocols (timing, concentration of activators)

• Include internal controls in each experiment (unstimulated vs. stimulated samples)

• Maintain consistent sample preparation and storage conditions

• Consider antibody lot-to-lot variability and validate new lots against previous standards

• Document exact experimental conditions for reproducibility

Problem 4: Poor Specificity for K221 Acetylation
Potential Solutions:

• Validate with acetylation-deficient K221R mutant as negative control

• Perform peptide competition assays with acetylated and non-acetylated peptides

• Compare with other K221 acetylation antibodies from different manufacturers

• Consider sequence similarities with other acetylation sites when interpreting results

Implementing these solutions should help researchers optimize experiments using Acetyl-RELA (K221) Antibody and obtain more reliable, reproducible results .

How should samples be prepared and stored to preserve RELA K221 acetylation for optimal antibody detection?

Proper sample preparation and storage are critical for preserving RELA K221 acetylation and achieving optimal antibody detection:

Cell/Tissue Lysis Protocol:

• Harvest cells quickly to minimize changes in acetylation status

• Prepare lysis buffer containing:

  • Deacetylase inhibitors: 1 μM TSA and 5 mM Nicotinamide

  • Protease inhibitors: 1 μg/ml each of pepstatin, bestatin, leupeptin, 1 mM PMSF

  • Phosphatase inhibitors: NaF, beta-glycerophosphate

  • Buffer composition: 20 mM HEPES pH 7.9, 100 mM NaCl, 2.5 mM MgCl₂, 0.05% NP-40

• Maintain samples on ice throughout processing

• Sonicate briefly if nuclear proteins are of interest

Protein Quantification and Storage:

• Determine protein concentration using Bradford or BCA assay

• Prepare aliquots to avoid freeze-thaw cycles

• Add SDS sample buffer with reducing agent

• Store samples at -80°C for long-term storage

Immunoprecipitation Considerations:

• Use 750 μg of extract with 1.5 μg of antibody for optimal results

• Maintain deacetylase inhibitors in all buffers throughout the procedure

• Keep incubation times as short as possible while ensuring efficient pull-down

• Consider using magnetic beads for gentler handling during wash steps

Pre-analytical Variables to Control:

• Standardize cell confluence and passage number

• Control stimulation conditions precisely (concentration, timing, temperature)

• Process all comparative samples simultaneously

• Document all variables that might affect acetylation status

Following these detailed protocols helps preserve the labile acetylation modification at K221 and ensures more consistent and reliable antibody detection across experiments .

What techniques can validate the specificity of Acetyl-RELA (K221) Antibody for research applications?

Validating the specificity of Acetyl-RELA (K221) Antibody is essential for reliable research outcomes. The following methodological approaches provide comprehensive validation:

Genetic Validation Methods:

• Mutation Analysis:

  • Compare signals between wild-type RELA and K221R mutant

  • The antibody should not detect the K221R variant

  • Include other acetylation site mutants (K310R, K314/315R) as controls

• Gene Silencing:

  • Analyze samples from RELA knockdown/knockout cells

  • Signal should be absent or significantly reduced

  • Reconstitution with wild-type RELA should restore signal

Biochemical Validation Methods:

• In Vitro Acetylation Assay:

  • Incubate recombinant RELA with p300 and acetyl-CoA

  • Compare reactions with and without acetyl-CoA

  • The antibody should only detect RELA in the complete reaction

• Peptide Competition:

  • Pre-incubate antibody with acetylated K221 peptide before Western blotting

  • Signal should be blocked by the specific peptide

  • Non-acetylated peptide should have minimal effect

• Deacetylase Treatment:

  • Treat immunoprecipitated RELA with purified deacetylases

  • The antibody signal should decrease after enzymatic deacetylation

Analytical Validation Methods:

• Mass Spectrometry Correlation:

  • Immunoprecipitate with the antibody and analyze by mass spectrometry

  • Confirm K221 acetylation in the immunoprecipitated material

  • Quantify the proportion of K221-acetylated peptides

• Antibody Cross-reactivity Panel:

  • Test reactivity against a panel of acetylated and non-acetylated proteins

  • Evaluate cross-reactivity with other acetylated lysines in similar sequence contexts

These validation approaches, used in combination, provide robust evidence for antibody specificity and reliability in various experimental applications .

How does RELA K221 acetylation impact gene expression patterns differently from other acetylation sites?

RELA K221 acetylation influences gene expression through distinct mechanisms compared to other acetylation sites:

Differential Genomic Targeting:
K221 acetylation enhances the DNA binding capacity of RELA , potentially altering its affinity for specific κB sites in the genome. This contrasts with K122/K123 acetylation, which reduces RelA binding to κB enhancers , and K314/K315 acetylation, which affects specific gene subsets without altering general DNA binding .

Nuclear Retention Mechanisms:
K221 acetylation (together with K218) impairs RELA's association with IκB proteins , promoting nuclear retention and prolonged transcriptional activity. This mechanism is distinct from K310 acetylation, which primarily enhances transcriptional activation without affecting IκB binding .

Co-regulator Recruitment Patterns:
Different acetylation sites likely recruit distinct transcriptional co-regulators:

• K221 acetylation may create binding surfaces for specific co-activators

• K310 acetylation is required for full transcriptional activity through different co-factor interactions

• K314/K315 acetylation differentially regulates specific gene subsets through unique protein-protein interactions

Temporal Dynamics of Gene Regulation:
Acetylation sites may operate with different kinetics:

• K221 acetylation might be important for early NF-κB target gene activation

• K314/K315 are implicated in late NF-κB dependent gene expression

• These temporal differences create a sequential gene activation program

Integration with Other Modifications:
K221 acetylation exists within a complex modification network:

• K221 can also be methylated by NSD1, which enhances NF-κB activity

• This creates potential competition between acetylation and methylation at the same residue

• K310 acetylation prevents methylation at K314/315, demonstrating cross-regulation between sites

Understanding these distinct mechanisms helps explain how different acetylation patterns create diverse gene expression outcomes despite occurring on the same transcription factor .

How might targeting enzymes that regulate RELA K221 acetylation affect inflammatory and immune responses?

Targeting enzymes that regulate RELA K221 acetylation represents a promising strategy for modulating inflammatory and immune responses:

Acetyltransferase Targeting Strategies:

• p300/CBP Modulation:

  • p300/CBP are primary acetyltransferases for RELA

  • Selective inhibitors could reduce K221 acetylation, potentially dampening NF-κB-mediated inflammation

  • Tissue-specific delivery of inhibitors might limit systemic side effects

  • Considerations must include effects on other p300/CBP substrates

• Enzyme Substrate Specificity:

  • Development of compounds that specifically block K221 acetylation without affecting other sites

  • Structure-based design of peptidomimetics that compete for K221 binding site

  • This approach may offer more selective anti-inflammatory effects

Deacetylase Targeting Approaches:

• Specific Deacetylase Activation:

  • Identify and activate deacetylases that preferentially target K221

  • Allosteric activators may enhance substrate specificity

  • This could reduce NF-κB activity in hyperinflammatory conditions

• Temporal Control of Deacetylation:

  • Develop strategies to modulate deacetylase activity at specific time points

  • This could help resolve inflammation without compromising initial immune responses

  • Inducible systems could provide controlled inflammatory resolution

Expected Immunological Outcomes:

• Acute Inflammation:

  • Reducing K221 acetylation might attenuate early inflammatory cytokine production

  • This could benefit conditions like sepsis or acute respiratory distress

• Chronic Inflammatory Diseases:

  • Modulating K221 acetylation might help reset dysregulated NF-κB signaling

  • Potential applications in rheumatoid arthritis, inflammatory bowel disease, and psoriasis

• Cancer Immunotherapy:

  • Selective enhancement of K221 acetylation might boost anti-tumor immune responses

  • Inhibiting deacetylation could promote sustained NF-κB activity in tumor-infiltrating lymphocytes

These approaches require careful consideration of:

• Cell-type specific effects on immune function

• Potential for compensatory mechanisms

• Timing of intervention in inflammatory cascades

• Integration with existing anti-inflammatory therapies

Targeting the enzymatic regulation of K221 acetylation offers a nuanced approach to modulating NF-κB signaling in immune and inflammatory disorders .

What are the current methodological challenges in studying the kinetics of RELA K221 acetylation in real-time cellular systems?

Investigating the real-time kinetics of RELA K221 acetylation presents several methodological challenges that require innovative approaches:

Current Technical Limitations:

• Antibody-Based Detection Constraints:

  • Traditional methods rely on fixed time-point sampling rather than continuous monitoring

  • Western blotting and immunofluorescence require cell fixation, preventing true real-time observation

  • Antibodies cannot access intracellular targets in living cells without permeabilization

• Signal-to-Noise Challenges:

  • Endogenous K221 acetylation may represent a small fraction of total RELA

  • Background fluorescence can mask subtle changes in acetylation status

  • Distinguishing specific K221 acetylation from other RELA modifications is technically difficult

• Temporal Resolution Limitations:

  • Current methods may miss rapid, transient acetylation events

  • Sample processing time introduces delays between stimulation and measurement

  • Cell-to-cell variability complicates population-level measurements

Emerging Methodological Solutions:

• Genetically Encoded Biosensors:

  • Development of FRET-based sensors specific for K221 acetylation

  • Design principles:

    • Position fluorophores to detect conformational changes upon acetylation

    • Incorporate acetyl-lysine binding domains (e.g., bromodomains)

    • Validate specificity against K221R mutants

• Live-Cell Acetylation Probes:

  • Cell-permeable chemical probes that selectively bind acetylated K221

  • Must demonstrate specificity over other acetylated lysines

  • Require minimal interference with normal RELA function

• Single-Cell Analysis Technologies:

  • Microfluidic platforms for sequential sampling from the same cell population

  • Integration with rapid cell fixation techniques

  • Coupling with high-content imaging for spatial information

• Advanced Mass Spectrometry Approaches:

  • SNAP-MS (Selected Reaction Monitoring of Acetyl Peptides)

  • Rapid sample processing workflows for minimizing post-stimulation changes

  • Targeted approaches to enhance sensitivity for specific acetylated peptides

• Computational Modeling:

  • Integration of experimental data with mathematical models

  • Prediction of acetylation/deacetylation kinetics under different conditions

  • Accounting for stochastic cell-to-cell variability

Addressing these challenges will require interdisciplinary approaches combining protein engineering, chemical biology, advanced microscopy, and computational methods to fully understand the dynamic regulation of RELA K221 acetylation in physiologically relevant contexts .

How do different cellular microenvironments affect RELA K221 acetylation patterns in disease states?

The influence of cellular microenvironments on RELA K221 acetylation patterns in disease states represents an important frontier in understanding context-specific NF-κB regulation:

Metabolic Microenvironment Factors:

• Acetyl-CoA Availability:

  • As the acetyl donor for acetyltransferases, fluctuations in acetyl-CoA levels directly impact acetylation capacity

  • Disease-specific metabolic alterations (e.g., cancer glycolysis, obesity) may alter acetyl-CoA pools

  • Acetylation patterns could serve as a sensor of cellular metabolic state

• NAD⁺ Levels and Sirtuin Activity:

  • NAD⁺-dependent deacetylases (sirtuins) may regulate K221 acetylation

  • Conditions altering NAD⁺/NADH ratio (aging, metabolic disorders) would affect deacetylation rates

  • Caloric restriction or exercise may influence K221 acetylation through NAD⁺ modulation

• Oxygen Tension:

  • Hypoxic microenvironments (tumors, ischemic tissue) alter acetylation enzyme activity

  • Cross-talk between HIF-1α and NF-κB pathways may involve K221 acetylation

  • Hypoxia-induced metabolic reprogramming affects acetyl-CoA metabolism and availability

Inflammatory Microenvironment Effects:

• Cytokine Milieu:

  • Different inflammatory cytokine combinations may induce distinct K221 acetylation patterns

  • Chronic vs. acute inflammation likely produces different temporal acetylation dynamics

  • Disease-specific cytokine profiles could create unique K221 acetylation signatures

• ROS and Oxidative Stress:

  • Oxidative stress modifies activity of acetylation/deacetylation enzymes

  • Redox-sensitive cysteine residues in these enzymes respond to microenvironmental ROS

  • This creates a link between oxidative stress and K221 acetylation regulation

Tissue-Specific Microenvironmental Factors:

• Extracellular Matrix Composition:

  • ECM-derived signals influence NF-κB activation and potentially K221 acetylation

  • Tissue fibrosis or remodeling alters these signals in disease states

  • Mechanotransduction pathways may converge on acetylation regulation

• Cell-Cell Interactions:

  • Direct contact with different cell types alters NF-κB signaling dynamics

  • Tumor-immune cell interactions create unique microenvironments affecting acetylation

  • Epithelial-stromal interactions in inflammatory diseases may generate tissue-specific patterns

Research Methodologies for Microenvironmental Studies:

• 3D Cell Culture Systems:

  • Organoid cultures to recapitulate tissue architecture

  • Co-culture systems with relevant cell types

  • Compare K221 acetylation patterns with 2D conventional cultures

• In Situ Detection Methods:

  • Multiplex immunohistochemistry with Acetyl-RELA (K221) antibody

  • Spatial transcriptomics to correlate acetylation with gene expression

  • Preservation of microenvironmental context during analysis

Understanding how different microenvironments influence K221 acetylation will provide insights into disease-specific NF-κB regulation and may suggest novel therapeutic approaches targeted to specific tissue contexts .